Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.42 |
| ▸ | CCR2 | P41597 | 9/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20088471 | 1.00 | SCN9A (0.54) | SCN9ATACR1CACNA1BCCR2CTSL | |
| SCHEMBL15843890 | 0.94 | SCN9A (0.57) | SCN9ATACR1CACNA1BCCR2MTOR | |
| SCHEMBL15843891 | 0.94 | SCN9A (0.57) | SCN9ATACR1CACNA1BCCR2MTOR | |
| SCHEMBL15844420 | 0.94 | SCN9A (0.57) | SCN9ATACR1CACNA1BCCR2MTOR | |
| SCHEMBL20088440 | 0.85 | SCN9A (0.50) | SCN9ATACR1CCR2MTOR | |
| SCHEMBL21565748 | 0.84 | TACR1 (0.53) | TACR1CCR2MTOR | |
| SCHEMBL17330317 | 0.84 | CACNA1B (0.55) | SCN9ACACNA1BCTSLANPEP | |
| SCHEMBL20088472 | 0.82 | TACR1 (0.49) | TACR1CCR2MTOR | |
| SCHEMBL20088469 | 0.79 | SCN9A (0.49) | SCN9ACACNA1BCTSL | |
| SCHEMBL15844542 | 0.76 | SCN9A (0.57) | SCN9ATACR1CCR2MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | SCN9A 52/4885TACR1 1462/4885CACNA1B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.